Coming Pharmaceutical (02105.HK) announced that its LAE123 has met the requirements for PCC (preclinical candidate compound) and has officially entered the IND-enabling study phase.

ActRII signaling dysregulation is associated with various diseases, including obesity, muscle wasting, and other serious diseases. The company will explore LAE123 as a new treatment for severe life-threatening diseases, such as pulmonary hypertension and spinal muscular atrophy.

LAE123 is a monoclonal antibody targeting the dual points of ActRIIA/IIB, effectively blocking the interaction between ActRIIA/IIB and its ligands (including myostatin, activin, and growth/differentiation indicators). As a highly effective monoclonal antibody targeting both ActRIIA and B, LAE123 demonstrated exceptional activity in reported gene assays (RGA) and showed excellent pharmacokinetics and efficacy in animal studies.